Samuel Flashner

Samuel Flashner is an Associate Research Scientist at the Herbert Irving Comprehensive Cancer Center, Columbia University. He earned his PhD in Molecular and Cellular Biology and Genetics and completed postdoctoral training at Columbia University, where he was an American Cancer Society Postdoctoral Fellow. His research focuses on esophageal squamous cell carcinoma (ESCC) initiation and progression, leveraging patient-derived 3D organoid libraries for high-throughput drug screening to identify therapeutic vulnerabilities, including the ATR-mediated DNA damage response pathway. His recent publications explore LIN28B-mediated PI3K/AKT signaling in colorectal cancer metastasis, alcohol-induced squamous field cancerization via Aldh2 and Trp53, and mitochondrial dysfunction in eosinophilic oesophagitis. He has presented his work at the AACR Annual Meeting and Gordon Research Conference, and received the 2024 award for Interstrand Crosslink Repair as a Squamous Cell Carcinoma Vulnerability.